Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the national cancer institute breast and prostate cancer cohort consortium

American Journal of Epidemiology

Volumn 175, Issue 9, 2012, Pages 926-935

  Tsilidis, Konstantinos K ^a   Travis, Ruth C ^a   Appleby, Paul N ^a   Allen, Naomi E ^a   Lindstrom, Sara ^b   Schumacher, Fredrick R ^c   Cox, David ^d,e   Hsing, Ann W ^f   Ma, Jing ^g   Severi, Gianluca ^h,i   Albanes, Demetrius ^b,f   Virtamo, Jarmo ^j   Boeing, Heiner ^k   Bueno De Mesquita, H Bas ^l,m   Johansson, Mattias ^n,o   Quirós, J Ramón ^p   Riboli, Elio ^e   Siddiq, Afshan ^e   Tjønneland, Anne ^q   Trichopoulos, Dimitrios ^r   Tumino, Rosario ^s   Gaziano, J Michael ^g,k,t   Giovannucci, Edward ^b,g   Hunter, David J ^b,g   Kraft, Peter ^b   Stampfer, Meir J ^b,g   Giles, Graham G ^h,i   Andriole, Gerald L ^u   Berndt, Sonja I ^f   Chanock, Stephen J ^f   Hayes, Richard B ^v   Key, Timothy J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CENTRE LÉON BÉRARD   (France)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h CANCER EPIDEMIOLOGY CENTRE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^k GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^l NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^o UMEÅ UNIVERSITY   (Sweden)

^p Public Health and Health Planning Directorate   (Spain)

^q INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^r BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^s CIVILE M P AREZZO HOSPITAL   (Italy)

^t VETERANS AFFAIRS MEDICAL CENTER   (United States)

^u WASHINGTON UNIVERSITY   (United States)

^v NEW YORK UNIVERSITY   (United States)

more..

Author keywords

gene environment interaction; gonadal steroid hormones; insulin like growth factor binding protein 3; insulin like growth factor I; molecular epidemiology; prostatic neoplasms

Indexed keywords

ANDROSTANEDIOL; ANDROSTANEDIOL GLUCURONIDE; ANDROSTENEDIONE; ESTRADIOL; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ALLELE; CANCER; CONCENTRATION (COMPOSITION); DISEASE CONTROL; ETIOLOGY; GENETIC VARIATION; GENOME; HEALTH RISK; MOLECULAR ANALYSIS; POLYMORPHISM; PROTEIN; SEX HORMONE;

AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; GENOME-WIDE ASSOCIATION STUDY; GONADAL STEROID HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN;

EID: 84860635417     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr423     Document Type: Article

References (42)

1. Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10): 1116-1121.
2. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-321.
3. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310-315.
4. Yeager M, Chatterjee N, Ciampa J, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009;41(10):1055- 1057.
5. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genomewide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009; 41(10):1122-1126.
6. Gudmundsson J, Sulem P, Manolescu A, et al. Genomewide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5): 631-637.
7. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281-283.
8. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8): 977-983.
9. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645-649.
10. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst. 2007;99(24):1836-1844.
11. Murabito JM, Rosenberg CL, Finger D, et al. A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet. 2007;8(suppl 1): S6. (doi:10.1186/1471-2350-8-S1-S6).
12. Nam RK, Zhang WW, Loblaw DA, et al. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(3):241-246.
13. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652-658.
14. Lindstrom S, Schumacher F, Siddiq A, et al. Characterizing associations and SNP-environment interactions for GWASidentified prostate cancer risk markers-results from BPC3. PLoS ONE. 2011;6(2):e17142. (doi:10.1371/journal. pone. 0017142).
15. Stevens VL, Ahn J, Sun J, et al. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate. 2010;70(6):601-607.
16. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149(7):461-471.
17. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol. 2004; 92(4):237-253.
18. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3): 170-183.
19. Chu LW, Meyer TE, Li Q, et al. Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1848- 1854.
20. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Nat Rev Cancer. 2005;5(12): 977-985.
21. Giles GG, English DR. The Melbourne Collaborative Cohort Study. IARC Sci Publ. 2002;156:69-70.
22. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003;63(14):3991-3994.
23. Dorgan JF, Albanes D, Virtamo J, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998;7(12):1069-1074.
24. Allen NE, Key TJ, Appleby PN, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1121-1127.
25. Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121(6):1331-1338.
26. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14(5): 1262-1269.
27. Platz EA, Pollak MN, Leitzmann MF, et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control. 2005; 16(3):255-262.
28. Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(1):86-91.
29. Severi G, Morris HA, MacInnis RJ, et al. Circulating insulinlike growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(6): 1137-1141.
30. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118-1126.
31. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advancedstage prostate cancer. J Natl Cancer Inst. 2002;94(14): 1099-1106.
32. Weiss JM, Huang WY, Rinaldi S, et al. IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2007;121(10):2267-2273.
33. Weiss JM, Huang WY, Rinaldi S, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008;122(10):2345- 2350.
34. Söderga°rd R, Bäckström T, Shanbhag V, et al. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16(6):801-810.
35. Rinaldi S, Geay A, Déchaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002;11(10):1065-1071.
36. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672.
37. Sun J, Zheng SL,Wiklund F, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009; 69(1):10-15.
38. Zheng SL, Stevens VL, Wiklund F, et al. Two independent prostate cancer risk-associated loci at 11q13. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1815-1820.
39. Paliwal S, Kovi RC, Nath B, et al. The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res. 2007;67(19):9322-9329.
40. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988-1004.
41. Siemiatycki J, Thomas DC. Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol. 1981;10(4):383-387.
42. Takata R, Akamatsu S, KuboM, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751-754.